论文部分内容阅读
目的分析耐多药肺结核患者的监测、治疗情况,为制定相关措施提供参考。方法通过痰培养和药物敏感性检测,在耐多药肺结核可疑患者中发现耐多药肺结核患者,对纳入患者进行为期2年的规范治疗管理,收集调查数据,分析患者治疗情况。结果共计检测1 046例可疑患者,在获得药敏结果的592例肺结核患者中,发现耐多药肺结核82例,耐多药率为13.9%;不同类别肺结核患者间发现的耐多药差异具有统计学意义(χ2=106.3,P<0.001);复发患者中发现的耐多药患者最多,占51.2%。共计纳入治疗53例,患者治疗成功率达57.1%。结论复发患者是耐多药筛查发现的重点对象,对耐多药患者实施全程的规范化治疗管理是获得治疗成功率的保证。
Objective To analyze the surveillance and treatment of MDR-TB patients and provide references for formulating relevant measures. Methods Through the sputum culture and drug susceptibility test, MDR-TB patients were found in suspicious patients with multi-drug-resistant pulmonary tuberculosis, and the patients were treated for 2-year standard treatment management. The survey data were collected to analyze the patient’s treatment. Results A total of 1 046 suspicious patients were detected. Among 592 pulmonary tuberculosis patients receiving drug susceptibility results, 82 were resistant to multi-drug pulmonary tuberculosis and the MDR rate was 13.9%. Differences in MDR among the different categories of tuberculosis patients were statistically significant Significance (χ2 = 106.3, P <0.001). The patients with multiple drug resistance were the most frequently found in relapse patients, accounting for 51.2%. A total of 53 cases were included in the treatment, the success rate of 57.1% of patients treated. Conclusion Recurrence patients are the key targets of multidrug-resistant screening. To standardize the management of multi-drug resistant patients is the guarantee of successful treatment.